Dare Bioscience (DARE) Projected to Post Earnings on Tuesday

Dare Bioscience (NASDAQ:DARE) is expected to post its Q1 2026 results after the market closes on Tuesday, May 12th. Analysts expect Dare Bioscience to post earnings of ($0.33) per share and revenue of $0.0270 million for the quarter. Individuals can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:30 PM ET.

Dare Bioscience (NASDAQ:DARE) last announced its quarterly earnings data on Thursday, March 26th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.42. The firm had revenue of $1.02 million during the quarter, compared to analyst estimates of $0.75 million.

Dare Bioscience Stock Performance

DARE traded up $0.22 during trading on Tuesday, hitting $3.33. The stock had a trading volume of 1,903,135 shares, compared to its average volume of 350,236. The firm has a market capitalization of $48.53 million, a P/E ratio of -2.61 and a beta of 1.09. The company’s 50-day moving average price is $1.78 and its 200 day moving average price is $1.87. Dare Bioscience has a twelve month low of $1.27 and a twelve month high of $9.19.

Hedge Funds Weigh In On Dare Bioscience

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Virtu Financial LLC acquired a new position in shares of Dare Bioscience during the 3rd quarter worth $37,000. Raymond James Financial Inc. grew its stake in shares of Dare Bioscience by 810.6% during the 3rd quarter. Raymond James Financial Inc. now owns 15,334 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 13,650 shares during the period. Finally, LPL Financial LLC acquired a new position in shares of Dare Bioscience during the 4th quarter worth $28,000. 6.70% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Dare Bioscience in a research note on Monday, April 20th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Dare Bioscience currently has an average rating of “Hold” and an average price target of $10.00.

Dare Bioscience Company Profile

Dare Bioscience, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for women’s reproductive health. The company’s flagship development candidate is Ovaprene, a monthly, self-administered, non-hormonal contraceptive vaginal ring designed to offer an alternative to traditional hormone-based birth control methods. Through its proprietary intravaginal drug delivery platform, Dare seeks to address unmet medical needs in gynecology and contraception with products that prioritize efficacy, safety and ease of use.

In addition to its lead contraceptive program, Dare is advancing a pipeline of early-stage assets aimed at treating gynecologic conditions through local, non-systemic drug delivery.